Subscribe: Market Wire - Medical and Healthcare: Surgery and Treatments
http://img.marketwire.com/rss/mwMHSU.rss
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
announced  announces  company  development  mar  march  marketwired mar  marketwired  medical  new  shares  technology  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Medical and Healthcare: Surgery and Treatments

Marketwired - Surgery and Treatments



Marketwired - Surgery and Treatments



Last Build Date: Wed, 29 Mar 2017 08:20:38 EDT

Copyright: Copyright: (C) Marketwired
 



Norfolk Ophthalmologists Offer New Treatment for Degenerative Eye Disease

Wed, 29 Mar 2017 08:01:00 EDT

Virginia Eye Consultants is one of the first practices in the state to employ Corneal Collagen Cross-Linking as a method of slowing or stopping the development of keratoconus




iHealth Innovations Acquires AllDocuments, Inc.

Wed, 29 Mar 2017 06:49:22 EDT

Adds offices in San Mateo, CA and Pittsburgh, PA




Elsevier Publishes Neural Data Science: A Primer with MATLAB(R) and Python(TM)

Wed, 29 Mar 2017 04:00:00 EDT

Beginner's introduction to the principles of computation and data analysis in neuroscience using both Python(TM) and MATLAB(R) is one of seven new neuroscience titles




Natural Beauty Announces 2016 Annual Results

Wed, 29 Mar 2017 02:05:01 EDT

Profit before tax up by 15.2% to HK$196.2 million; Enhanced brand equity of NB to support long-term growth




Ritter Pharmaceuticals Announces Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial

Tue, 28 Mar 2017 18:28:22 EDT

LOS ANGELES, CA--(Marketwired - Mar 28, 2017) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR)




Medtronic, DePuy Synthes Lead Cervical and Lumbar Artificial Disc Market Due to Positive Clinical Results and Emerging Technologies

Tue, 28 Mar 2017 12:27:58 EDT

Overall, the U.S. spinal implants and vertebral compression fracture market is expected to increase and reach nearly $7 billion by 2023




LogixHealth Publishes ED Facility-Focused Intelligence Briefing: 2017 Emergency Department Outpatient Payment System Update

Tue, 28 Mar 2017 12:00:00 EDT

BEDFORD, MA--(Marketwired - Mar 28, 2017) - LogixHealth, a leading provider of internet and software enabled coding, billing, analytics and management services for hospital and physician practices nationwide, provides services for millions of Emergency Department (ED) visits nationwide, and has published its newest facility-focused intelligence briefing: 2017 Emergency Department Outpatient Payment System Update. On November 1, 2016, CMS published the 2017 Outpatient Prospective Payment System (OPPS) final rule in the Federal Register, which finalizes payment rates and policies for outpatient services furnished by hospitals that are paid under the OPPS, and governs services provided on or after January 1, 2017. The rule, and the full 2017 Emergency Department Outpatient Payment System Update can be found on the LogixHealth website.




Tauriga Sciences Inc. Secures More than $100,000 USD of Additional Funding from Existing Institutional & Accredited Individual Investors

Tue, 28 Mar 2017 11:56:11 EDT

NEW YORK, NY--(Marketwired - Mar 28, 2017) - Tauriga Sciences Inc. (OTC PINK: TAUG) ("Tauriga" or "the Company"), a Company engaged in building businesses in the life sciences space, has today announced that it has secured additional financing in excess of $100,000 USD from two existing institutional investors as well as one accredited individual investor. This is a significant development for the Company, at this time, because it enables the Company to commence the audit work pertaining to its Fiscal Year 2017 ("FY '17") Year End (Period Ending March 31, 2017) in a timely manner. This substantially reduces the possibility of the Company becoming delinquent in filing its upcoming periodic SEC Filing(s). It also helps the Company work towards the achievement of its most important corporate milestones; defined as: the successful prosecution of its ongoing litigation ("the lawsuit") against its predecessor audit firm Cowan Gunteski & Co. PA ("Cowan Gunteski") and the evaluation of potentially lucrative business opportunities to create shareholder value. The Company also believes that it has effectively preempted a major potential risk to shareholders by successfully addressing the issue of financing its FY '17 audit work at this relatively early period of time.




NSAV Announces Cancellation of 3.0 Billion KBM Worldwide Shares

Tue, 28 Mar 2017 10:22:38 EDT

CRESCO, PA--(Marketwired - Mar 28, 2017) - Net Savings Link, Inc. (OTC: NSAV) announced today that the Company has cancelled 3.0 billion shares of its common stock that had been pledged to KBM Worldwide in a settlement negotiated by the Company's previous management. The Company took this action as these shares were part of an agreement between NSAV and its former management and China Food and Beverage Company (OTC: CHIF). The agreement expired on June 30, 2016 and is now null and void. The Company feels that this action is in the best interest of NSAV and its shareholders.




Étude de cohorte de plus de sept millions de dollars relative à la progression de la SP et visant à transformer le paysage de la SP au Canada

Tue, 28 Mar 2017 09:00:00 EDT

La Société canadienne de la SP, Biogen Canada et la Fondation Brain Canada s'associent pour financer la première étude de cohorte qui sera menée au Canada sur la progression de la sclérose en plaques




$7+ million MS Progression Cohort to change the face of MS in Canada

Tue, 28 Mar 2017 09:00:00 EDT

MS Society of Canada, Biogen Canada, and Brain Canada partner to support the first Canadian cohort that will study the progression of multiple sclerosis over time




First Choice Healthcare Solutions to Present at the Microcap Conference on April 4, 2017 in New York City

Tue, 28 Mar 2017 08:30:00 EDT

MELBOURNE, FL--(Marketwired - Mar 28, 2017) - First Choice Healthcare Solutions, Inc. (OTCQB: FCHS) ("FCHS," "First Choice" or the "Company"), one of the nation's only non-physician-owned, publicly traded healthcare services companies focused on the delivery of total musculoskeletal solutions with an emphasis on Orthopaedics and Spine care, today announced that its President and Chief Executive Officer, Chris Romandetti, has been invited to present at this year's MicroCap Conference to be held in New York City at the Essex House on April 4, 2017.




Propanc Receives Patentability Opinion for Method of Treating Cancer Stem Cells

Tue, 28 Mar 2017 08:30:00 EDT

International Search Report concludes majority of claims are novel and inventive




Del Mar Dermatologist Launches Mobile App and Loyalty Program

Tue, 28 Mar 2017 08:01:00 EDT

Deborah H. Atkin, MD of Dermatology & Laser of Del Mar recently developed and launched a mobile app that allows patients to accrue points for products and services and schedule appointments, among other benefits




MJTV Begins, "What Is A Beautiful Woman", Branding And Marketing Campaign In Advance Of VOLUPTAS Market Launch

Tue, 28 Mar 2017 08:00:00 EDT

WHIPPANY, NJ--(Marketwired - Mar 28, 2017) - Michael James Enterprises, Inc. (OTCQB: MJTV) launches, "What is a Beautiful Woman" branding and marketing campaign in advance of the VOLUPTAS market launch. After much time and thought and conferring with different experts and groups MJTV has set out to describe through an image as a company-wide focus on "What is a Beautiful Woman". Shelley Rizzo, the graphic designer, collaborated with MJTV Chief Operating Officer, Gina Morreale, on the design and descriptive words of the new logo. They also decided to name her -- "BEAUTY".




Nu-Med Plus files 8-K Disclosure

Tue, 28 Mar 2017 08:00:00 EDT

SALT LAKE CITY, UT--(Marketwired - March 28, 2017) - Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device development company, announced the filing of a form 8-K with the Securities and Exchange Commission regarding legal action.




Zenosense, Inc.: MIDS Medical Engages Future Diagnostics for Assay Consulting Services

Tue, 28 Mar 2017 07:30:00 EDT

VALENCIA, SPAIN--(Marketwired - Mar 28, 2017) - Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and commercialization of MIDS CardiacT, a Point of Care ("POC") handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected acute myocardial infarction (heart attack), is pleased to announce that MIDS Medical Limited ("MML"), our joint venture based at Sci-Tech, Daresbury (UK), has engaged Future Diagnostics Solutions B.V. ("Future Diagnostics") for assay development services.




NFANT Labs Named a TAG Top 10 Innovative Technology Company

Tue, 28 Mar 2017 07:00:00 EDT

ATLANTA, GA--(Marketwired - Mar 28, 2017) - The Technology Association of Georgia (TAG), the state's leading association dedicated to the promotion and economic advancement of Georgia's technology industry, named NFANT Labs as the Breakthrough Technology of the Year and one of its Top 10 Innovative Technology Companies in Georgia at the 2017 Georgia Technology Summit (GTS) on March 23, 2017.




Surveyed Top 50 Pharma and Biotech Companies Report Average Per-Patient Costs of $57,500 During Non-Adaptive Phase 1 Studies

Mon, 27 Mar 2017 19:28:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - March 27, 2017) - Surveyed pharmaceutical, biotech, and device companies expend up to $120,000 per patient during Phase 1 non-adaptive studies, according to recent data published by business intelligence firm Cutting Edge Information. Comparing survey responses for Phase 1 adaptive design clinical trials shows that companies typically expect to spend no more than $80,000 per patient.




CBIS Ramps Up Production and Releases More New Products to Meet the Substantial Requests From Self-Medicating Patients Across the Country as it Highlights Moonlight Cannabis as its Newest Spotlight Dispensary for the Month of April 2017

Mon, 27 Mar 2017 15:40:40 EDT

CBIS Sets the Stage to Meet the Increasing Consumer Demand With Even More Medicinal Products for its Nationwide Observational and Clinical Studies




Inaugural Medical Sensors Design Conference Comes to Boston in May

Mon, 27 Mar 2017 14:00:00 EDT

Premier Resource for the Sensors Industry to Host Multi-Day Event on Sensor Innovations and Opportunities in Medical and Healthcare Applications




Hearing Industries Association (HIA) Response to the Over-the-Counter Hearing Aid Act of 2017

Mon, 27 Mar 2017 12:00:00 EDT

WASHINGTON, DC--(Marketwired - March 27, 2017) - On March 20, 2017 the Over-the-Counter Hearing Aid Act of 2017 (S.670) was introduced by Senators Elizabeth Warren (D-Mass.), Charles Grassley (R-Iowa), Maggie Hassan (D-N.H.) and Johnny Isakson (R-Ga.). The bill would require the Food and Drug Administration (FDA) to propose a rule to establish an over-the-counter hearing aid (OTC) category for adults with "perceived" mild to moderate hearing loss within three years of passage of the legislation. Representatives Joseph Kennedy III (D-Mass.) and Marsha Blackburn (R-Tenn.) have introduced an Over-the-Counter Hearing Aid bill (H.R. 1652) in the House, which mirrors the Senate bill.




GeoVax Reports on Vaccine Development Progress

Mon, 27 Mar 2017 09:00:00 EDT

Expanding Pipeline for MVA-VLP Vaccine Platform Includes HIV, Zika, Ebola, Malaria, Hepatitis B and Cancer




Advantis Corp. Expands Product and Distribution Channels

Mon, 27 Mar 2017 09:00:00 EDT

NEWPORT BEACH, CA--(Marketwired - Mar 27, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) is partnering with a new cooperative group that is licensed to operate in San Diego. The cooperative, who will be carrying various expanded Advantis product lines, is a technology based delivery service that delivers medical marijuana to its members anywhere in the city within two hours.




Protext Mobility Announces Acquisition of Cannabis Biosciences Inc.

Mon, 27 Mar 2017 08:00:00 EDT

BOCA RATON, FL--(Marketwired - Mar 27, 2017) - Protext Mobility, Inc. (OTC PINK: TXTM) ("Protext" or "the Company"), a biotech company engaged in the development of pharmaceutical applications for the highly bioavailable Phytofare® catechin complex, today announced its acquisition of Cannabis Biosciences Inc. from Plandaí Biotechnology Inc. Under the terms of the transaction, Protext acquired 100% of the capital stock of Cannabis Biosciences in exchange for 50 million shares of its common stock. Plandaí has indicated that the shares acquired from Protext will be distributed to Plandaí shareholders as a stock dividend. Protext will now operate its two wholly owned subsidiaries as independent operating businesses. The new business unit, Cannabis Biosciences, will focus on developing cannabis extracts under legal government licenses and permits which the Company is currently pursuing. Plandaí Biotechnology South Africa, the other business unit, is engaged in the research and clinical testing of "bioceutical" products -- all natural ingredients formulated for pharmaceutical applications and processed under pharma-grade conditions. The Company has the exclusive worldwide license to develop pharmaceutical applications and products using the Phytofare® catechin complex produced from green tea grown on the Senteeko estate.




BriaCell Closes CEO Equity Investment

Fri, 24 Mar 2017 18:22:47 EDT

BERKELEY, CA and VANCOUVER, BC--(Marketwired - March 24, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce it has completed its previously announced non-brokered private placement financing (the "Offering") of 5,612,083 units (the "Units") for aggregate gross proceeds to the Company in the amount of $1,346,900 with its President and CEO, Dr. William Williams.




Kessler Foundation Renews Collaboration with Children's Specialized Hospital

Fri, 24 Mar 2017 14:08:11 EDT

EAST HANOVER, NJ and NEW BRUNSWICK, NJ--(Marketwired - March 24, 2017) - Kessler Foundation, a global leader in rehabilitation research, and Children's Specialized Hospital, the nation's leading provider of inpatient and outpatient care for children facing special health challenges, have renewed their collaboration by signing a three-year agreement, with a funding level of $2.1 million, to continue their research program for children with disabilities.




GeoVax Reports 2016 Year-End Financial Results

Fri, 24 Mar 2017 14:00:00 EDT

ATLANTA, GA--(Marketwired - Mar 24, 2017) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the year ended December 31, 2016.




NSAV Announces 2.5 Billion Share Reduction

Fri, 24 Mar 2017 10:31:40 EDT

CRESCO, PA--(Marketwired - Mar 24, 2017) - Net Savings Link, Inc. (OTC: NSAV) announced today that the Company has approved a 2.5 billion reduction of its authorized shares. The Company took this action after lengthy consultation with its attorneys, investment bankers and advisers, in order to ensure that the amount of the share reduction benefits all NSAV shareholders, while still allowing the Company to grow and make acquisitions. The Company wants to reassure all of its shareholders that no substantial dilution of its shares has taken place or will take place and that NSAV is not planning or even considering a reverse split of its shares.




NetworkNewsWire Announces Publication of Discussion on the Potential of Immunotherapies for Cancer Treatment

Fri, 24 Mar 2017 08:30:00 EDT

NEW YORK, NY--(Marketwired - Mar 24, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring TapImmune, Inc. (NASDAQ: TPIV), an NNW client focused on leading the field of oncology with its next-generation T-cell vaccines and novel immunotherapy platforms.




Medigus Announces $7.5 Million Public Offering

Fri, 24 Mar 2017 07:26:11 EDT

OMER, ISRAEL--(Marketwired - Mar 24, 2017) -  Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced the pricing of a best efforts public offering of 979,714 Class A Units at a purchase price per unit of $3.50 and of 1,163,144 Class B Units at an effective purchase price per unit of $3.50. Each Class A unit consists of (i) one American Depositary Share, or ADS, and (ii) one Series A warrant to purchase one ADS, and each Class B unit consists of (i) one pre-funded warrant to purchase one ADS, and (ii) one Series A warrant to purchase one ADS. The offering is expected to result in gross proceeds to the company of approximately $7.5 million.




HCi Viocare Ships its 4th Generation Athletic Smart Insole

Thu, 23 Mar 2017 16:00:00 EDT

GLASGOW, SCOTLAND--(Marketwired - Mar 23, 2017) - HCi Viocare (OTCQB: VICA) is pleased to announce that its wholly owned subsidiary HCi Viocare Technologies, the company behind the revolutionary sensing technology FlexisenseT,  has started shipping its 4th Generation Athletic Smart insoles to the sports shoes manufacturers with whom the company is in discussions.




SNS FiRe Conference Names ElpisEremo a 2017 FiReStarter Company

Thu, 23 Mar 2017 15:13:20 EDT

Global thought leaders converge this October to address some of the world's greatest challenges




True Nature Expands Advisory Board, Appoints Investment Professional With Medical Clinic and Emerging CBD Marketplace Knowledge Base in Hispanic Markets

Thu, 23 Mar 2017 14:36:31 EDT

ATLANTA, GA--(Marketwired - Mar 23, 2017) -  True Nature Holding, Inc. (OTCQB: TNTY) (the "Company") announced today that it has expanded its non-executive Advisory Board with the addition of Mr. Leo Smith, who is based in Fort Lauderdale, Florida. Mr. Smith has extensive experience in rapid growth situations, in both public and private companies, and most recently has invested in both medical clinics and the emerging marijuana area. His experience extends past the US marketplaces, into the South American economies, and has a pulse on the expanding Hispanic communities in the US as well.




Pressure BioSciences, Inc. Significantly Expands Marketing and Sales Capabilities

Thu, 23 Mar 2017 10:27:22 EDT

Company Engages Highly-Regarded Lead Generation Service and Hires the First Two of Four Field Sales Directors, Executing on its Plan to Aggressively Enhance Product Sales Capabilities in 2017




Dr. Brita Hansen joins LogicStream Health as Chief Medical Officer

Thu, 23 Mar 2017 10:00:00 EDT

MINNEAPOLIS, MN--(Marketwired - Mar 23, 2017) - LogicStream Health, Inc. is pleased to announce Dr. Brita Hansen is the company's new Chief Medical Officer. Dr. Hansen comes to LogicStream from Hennepin County Medical Center (HCMC), where she served as Chief Health Information Officer. Prior to her role as CHIO, Dr. Hansen spent many years in quality improvement as the Medical Director of Inpatient Quality and Informatics at HCMC. She is also an assistant professor of medicine at the University of Minnesota School of Medicine.




Dr. Brita Hansen joins LogicStream Health as Chief Medical Officer

Thu, 23 Mar 2017 10:00:00 EDT

MINNEAPOLIS, MN--(Marketwired - Mar 23, 2017) -  LogicStream Health, Inc. is pleased to announce Dr. Brita Hansen is the company's new Chief Medical Officer. Dr. Hansen comes to LogicStream from Hennepin County Medical Center (HCMC), where she served as Chief Health Information Officer. Prior to her role as CHIO, Dr. Hansen spent many years in quality improvement as the Medical Director of Inpatient Quality and Informatics at HCMC. She is also an assistant professor of medicine at the University of Minnesota School of Medicine.




Endonovo Therapeutics Files a New Patent Application on Method to Treat Tissues and Organs Using Its Non-Invasive Electroceutical Technology

Thu, 23 Mar 2017 09:29:00 EDT

Company Provides Update on The Development of Its Pipeline of Non-Invasive Electroceuticals Targeting Vascular Diseases and Ischemia/Reperfusion Injuries




Predictive Technology Group, Inc. (PRED) Announces Development Progress of its Non-Invasive DNA Test for Endometriosis in Three Scientific Presentations

Thu, 23 Mar 2017 09:15:00 EDT

Development of the ARTGuide(R) Test for Endometriosis Test Will Rapidly Accelerate Short and Long-Term Company Growth




NetworkNewsWire Announces Publication of Editorial on Advantages, Challenges of Big Data in Health Care

Thu, 23 Mar 2017 08:46:58 EDT

NEW YORK, NY--(Marketwired - Mar 23, 2017) -  NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ORHub, Inc. (OTC: ORHB), an NNW client providing its cloud-based health care software-as-a-service (SaaS) to decrease costs and improve outcomes in surgical care.




Titan Medical Finalizes User Requirements for 1st Generation Robotic Surgical System; Reiterates 2017 and 2018 Development Milestones Leading to FDA 510(k) Submission

Thu, 23 Mar 2017 08:32:26 EDT

TORONTO, ON--(Marketwired - March 23, 2017) - Titan Medical Inc. (TSX: TMD) (OTCQX: TITXF), reported today that the first milestone for 2017, finalizing user requirements for the single port robotic surgical system, has been achieved slightly ahead of schedule. The Company also reiterated the development milestones Titan is pursuing for its single-port robotic surgical system for application in minimally invasive surgery (MIS). The milestones and timeline are designed to lead to Titan's 510(k) submission to the US Food & Drug Administration (FDA) for clearance to market.




Brazilian Butt Lift: Jacksonville Plastic Surgeons Explain the Benefits of Buttock Augmentation

Thu, 23 Mar 2017 08:01:00 EDT

Doctors with Florida Plastic Surgery Group say the Brazilian Butt Lift can help patients enhance fullness and contour to the buttocks without the need for implants




Pressure BioSciences, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Provides Business Update

Wed, 22 Mar 2017 12:34:20 EDT

55% Growth in Q4 2016 Products & Services Revenue, Including 70% Increase in Sale of Consumable Supplies, Helps Company Achieve 27% Growth in Products & Services Revenue for Fiscal Year 2016

New Product Releases and Expansion of Sales & Marketing Capabilities Expected to Augment Revenue in FY2017

Investor Conference Call Scheduled for Wednesday, March 22, 2017 at 4:30 PM EDT




Viveve Announces Closing of Public Offering of Shares of Common Stock

Wed, 22 Mar 2017 11:00:00 EDT

SUNNYVALE, CA--(Marketwired - March 22, 2017) - Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced the closing of its previously announced underwritten public offering of 8,625,000 shares of its common stock at a public offering price of $4.00 per share, including shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional shares. Viveve estimates net proceeds from the offering will be approximately $31.7 million, after deducting underwriting discounts and commissions and estimated offering expenses.




Cyrex Laboratories Unveils Array 22 in Canada for Unprecedented Accuracy in Assessing SIBO

Wed, 22 Mar 2017 10:30:00 EDT

New Serum Test Identifies Small Intestine Bacterial Overgrowth (SIBO) to Help Treat Patients Suffering from Irritable Bowels, Malabsorption, Fatigue and More




Cyrex Laboratories Unveils Array 22 for Unprecedented Accuracy in Assessing SIBO

Wed, 22 Mar 2017 10:00:00 EDT

New Serum Test Identifies Small Intestine Bacterial Overgrowth (SIBO) to Help Treat Patients Suffering from Irritable Bowels, Malabsorption, Fatigue and More




TissueGen Featured in Nature.com Webcast on Innovations in Drug Delivery Technology

Wed, 22 Mar 2017 10:00:00 EDT

TissueGen's ELUTE Fiber Provides Controlled Sustained Delivery of Sensitive Drugs Enabling Nerve Regeneration and Tissue Engineering




Advantis Corp. To Introduce New Line of Concentrate-Infused Products, CEO to Be Interviewed on Small Cap Voice

Wed, 22 Mar 2017 09:00:00 EDT

NEWPORT BEACH, CA--(Marketwired - Mar 22, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) is introducing a new line of premium concentrate-infused products that it will make available through its existing business partners, before kicking off a new marketing campaign. Advantis CEO, Christopher Swartz will comment further on this product line along with providing a future outlook and shareholder update on Small Cap Voice next week.




NEMUS Bioscience and the University of Mississippi Announce Significant Anti-MRSA Synergy Data Utilizing Proprietary Cannabinoid-Based Anti-Infective Platforms

Wed, 22 Mar 2017 08:30:00 EDT

COSTA MESA, CA--(Marketwired - Mar 22, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) and the company's discovery and research partner, the University of Mississippi (UM), today announced that bactericidal synergy was achieved against multiple species of methicillin-resistant Staphylococcus aureus (MRSA) utilizing a proprietary cannabinoid-based therapeutic platform. MRSA species tested included community acquired- (CA-MRSA), healthcare-acquired- (HA-MRSA), and mupirocin-resistant (MR-MRSA) strains of MRSA. 




National Brain Tumor Society Launches New Brain Tumor-Specific Clinical Trial Finder

Wed, 22 Mar 2017 08:30:00 EDT

New tool will make it easier for brain tumor patients to find up-to-date information on clinical trials, enabling patients to better engage with medical research and make more informed decisions about their own treatment options in the era of precision medicine